Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANHEPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANHEPRIN.
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANHEPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting blood coagulation.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
80 units/kg IV bolus followed by 18 units/kg/hour continuous IV infusion; adjust to maintain aPTT 1.5-2.5 times control.
None Documented
None Documented
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
Terminal elimination half-life is dose-dependent: at standard IV doses (100 U/kg), mean t½ = 60 min (range 40–90 min); at high doses (400 U/kg), t½ increases to 150 min due to saturable clearance mechanisms. Clinical context: Short t½ necessitates continuous infusion or frequent subcutaneous dosing for sustained anticoagulation.
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Primarily renal excretion of metabolites (desulfated heparin) with a minor biliary/fecal component. Unchanged heparin is not excreted renally; clearance occurs via saturable hepatic metabolism and reticuloendothelial system uptake. Renal excretion accounts for approximately 50% of total clearance at therapeutic doses, while biliary/fecal elimination is <10%.
Category A/B
Category C
Anticoagulant
Anticoagulant